Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies, Inc. iRhythm sold 1,575,342 shares of its common stock, including shares sold pursuant to the full exercise of the underwriters’ over-allotment option, for total gross proceeds of $115 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IRTC.”
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining its wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. iRhythm is based in San Francisco, California.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Bryan M. Quinn and Daniel Fox. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included partner David R. Bauer and associate Gianna C. Walton. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.